Effects of interleukin-6 on mobilization of primitive haemopoietic cells into the circulation.
Authors
Pettengell, RuthLuft, Thomas
De Wynter, Erika A
Coutinho, Lucia H
Young, Rosemary
Fitzsimmons, Lesley
Scarffe, J Howard
Testa, Nydia G
Affiliation
CRC Department of Medical Oncology, Christie Hospital, Manchester.Issue Date
1995-02
Metadata
Show full item recordAbstract
Twenty-seven patients with advanced adenocarcinoma were studied. Groups of three patients received interleukin-6 (IL-6) in doses ranging from 0.5 to 20 micrograms/kg by daily subcutaneous injection on days 1-7 and 22-49. Four patients received IL-6 2.5 micrograms/kg/d with GM-CSF 5 micrograms/kg/d and three patients received IL-6 2.5 micrograms/kg/d with IL-3 5 micrograms/kg/d. Circulating platelet numbers increased 1.65-fold during IL-6 treatment, in a dose-dependent fashion (P = 0.01). This increase is inferior to that expected from laboratory studies. No significant change in total WBC was seen after IL-6 alone. After treatment with IL-6, significant increases in numbers of circulating mononuclear cells (2.2-fold, P = 0.006) and GM-CFC numbers (3.2-fold, P = 0.01) were seen, but there were no changes in circulating megakaryocyte-CFC numbers. In contrast, after treatment with IL-6 and GM-CSF, larger increases in both circulating GM-CFC (20-fold, P = 0.04) and megakaryocyte-CFC numbers (18-fold, P = 0.03) were seen. Increases in blood progenitors after treatment with IL-6 and IL-3 did not achieve statistical significance. The ability of peripheral blood mononuclear cells to generate and sustain long-term haemopoiesis in vitro was similar in IL-6-treated patients to that in untreated control subjects. No significant changes in the incidence of bone marrow progenitors or their cycling status (assessed by thymidine suicide) were seen. These data suggest that IL-6 alone will not be clinically useful to mobilize blood progenitor cells in cancer patients.Citation
Effects of interleukin-6 on mobilization of primitive haemopoietic cells into the circulation. 1995, 89 (2):237-42 Br. J. Haematol.Journal
British Journal of HaematologyDOI
10.1111/j.1365-2141.1995.tb03295.xPubMed ID
7873372Type
ArticleLanguage
enISSN
0007-1048ae974a485f413a2113503eed53cd6c53
10.1111/j.1365-2141.1995.tb03295.x
Scopus Count
Collections
Related articles
- Effect of interleukin-3 pretreatment on granulocyte/macrophage colony-stimulating factor induced mobilization of circulating haemopoietic progenitor cells.
- Authors: Geissler K, Peschel C, Niederwieser D, Goldschmitt J, Hladik F, Fritz A, Ohler L, Bettelheim P, Huber C, Lechner K
- Issue date: 1995 Oct
- Haemopoietic progenitor and myeloid cell kinetics in humans treated with interleukin-3 and granulocyte/macrophage colony-stimulating factor in combination.
- Authors: Lord BI, Testa NG, Bretti S, Chang J, Demuynck H, Coutinho L, de Campos E, Fitzsimmons L, Scarffe JH
- Issue date: 1994 Nov 15
- Interactions among colony-stimulating factors, IL-1 beta, IL-6, and kit-ligand in the regulation of primitive murine hematopoietic cells.
- Authors: Muench MO, Schneider JG, Moore MA
- Issue date: 1992 Mar
- The effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer.
- Authors: Gheilmini M, Pettengell R, Coutinho LH, Testa N, Crowther D
- Issue date: 1996 Apr
- The relationship between different high proliferative potential colony-forming cells in mouse bone marrow.
- Authors: Kriegler AB, Verschoor SM, Bernardo D, Bertoncello I
- Issue date: 1994 May